A new vaccine therapy has the potential to generate immune responses in patients with head and neck squamous cell carcinoma, or HNSCCa, in patients with the human papillomavirus, or HPV.
Researchers at the Abramson Cancer Center of the University of Pennsylvania created the new vaccine to generate immune responses in patients with HNSCCa by targeting HPV, a sexually-transmitted disease, which is associated with HNSCCa.
